JP2022533438A5 - - Google Patents

Info

Publication number
JP2022533438A5
JP2022533438A5 JP2021569402A JP2021569402A JP2022533438A5 JP 2022533438 A5 JP2022533438 A5 JP 2022533438A5 JP 2021569402 A JP2021569402 A JP 2021569402A JP 2021569402 A JP2021569402 A JP 2021569402A JP 2022533438 A5 JP2022533438 A5 JP 2022533438A5
Authority
JP
Japan
Prior art keywords
aav
acid sequence
amino acid
protein
capsid protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021569402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533438A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/034328 external-priority patent/WO2020242984A1/en
Publication of JP2022533438A publication Critical patent/JP2022533438A/ja
Publication of JP2022533438A5 publication Critical patent/JP2022533438A5/ja
Priority to JP2024196799A priority Critical patent/JP2025032110A/ja
Priority to JP2025085876A priority patent/JP2025119015A/ja
Pending legal-status Critical Current

Links

JP2021569402A 2019-05-24 2020-05-22 改変ウイルス粒子およびその使用 Pending JP2022533438A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024196799A JP2025032110A (ja) 2019-05-24 2024-11-11 改変ウイルス粒子およびその使用
JP2025085876A JP2025119015A (ja) 2019-05-24 2025-05-22 改変ウイルス粒子およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852791P 2019-05-24 2019-05-24
US62/852,791 2019-05-24
PCT/US2020/034328 WO2020242984A1 (en) 2019-05-24 2020-05-22 Modified viral particles and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024196799A Division JP2025032110A (ja) 2019-05-24 2024-11-11 改変ウイルス粒子およびその使用

Publications (2)

Publication Number Publication Date
JP2022533438A JP2022533438A (ja) 2022-07-22
JP2022533438A5 true JP2022533438A5 (cg-RX-API-DMAC7.html) 2023-05-30

Family

ID=71094822

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021569402A Pending JP2022533438A (ja) 2019-05-24 2020-05-22 改変ウイルス粒子およびその使用
JP2024196799A Pending JP2025032110A (ja) 2019-05-24 2024-11-11 改変ウイルス粒子およびその使用
JP2025085876A Pending JP2025119015A (ja) 2019-05-24 2025-05-22 改変ウイルス粒子およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024196799A Pending JP2025032110A (ja) 2019-05-24 2024-11-11 改変ウイルス粒子およびその使用
JP2025085876A Pending JP2025119015A (ja) 2019-05-24 2025-05-22 改変ウイルス粒子およびその使用

Country Status (19)

Country Link
US (1) US20220241430A1 (cg-RX-API-DMAC7.html)
EP (1) EP3976631A1 (cg-RX-API-DMAC7.html)
JP (3) JP2022533438A (cg-RX-API-DMAC7.html)
KR (1) KR20220011664A (cg-RX-API-DMAC7.html)
CN (2) CN113874386A (cg-RX-API-DMAC7.html)
AR (2) AR118997A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020283537A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021023692A2 (cg-RX-API-DMAC7.html)
CA (1) CA3140386A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021003096A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017692A2 (cg-RX-API-DMAC7.html)
IL (1) IL288233A (cg-RX-API-DMAC7.html)
MA (1) MA56035A (cg-RX-API-DMAC7.html)
MX (1) MX2021014338A (cg-RX-API-DMAC7.html)
PE (1) PE20212357A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552887A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112917PA (cg-RX-API-DMAC7.html)
TW (1) TW202110869A (cg-RX-API-DMAC7.html)
WO (1) WO2020242984A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12421525B2 (en) 2018-02-28 2025-09-23 University of Pittsburgh—of the Commonwealth System of Higher Education Conjugates comprising AAVs and CAS9 polypeptides
AU2020283537A1 (en) * 2019-05-24 2021-12-16 Regeneron Pharmaceuticals, Inc. Modified viral particles and uses thereof
US20240124892A1 (en) * 2021-03-02 2024-04-18 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Adeno-associated viruses and methods and materials for making and using adeno-associated viruses
US20250195693A1 (en) * 2021-04-30 2025-06-19 Duke University Compositions Comprising Adeno-Associated Virus Chimera Capsid Proteins and Methods of Using the Same
EP4359550A1 (en) * 2021-06-23 2024-05-01 Dyno Therapeutics, Inc. Capsid variants and methods of using the same
AU2023269134A1 (en) 2022-05-09 2024-12-12 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
EP4766849A2 (en) * 2023-08-24 2026-07-01 Ohio State Innovation Foundation Dosages and quality control methods for genome encapsidation for gene therapy purposes
CN121794393A (zh) * 2023-09-07 2026-04-03 里珍纳龙药品有限公司 经共价表面修饰的腺相关病毒的生产和纯化
WO2025111473A1 (en) * 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus
WO2026037757A1 (en) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag Modified aav particles
WO2026112457A2 (en) * 2024-11-21 2026-05-28 Regeneron Pharmaceuticals, Inc. Heterodimeric antigen-binding molecules that bind to viral particles and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261554B1 (en) * 1995-07-25 2001-07-17 Introgene B.V. Compositions for targeted gene delivery
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
DE69939169D1 (de) 1998-05-28 2008-09-04 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
DE69936104T2 (de) 1998-11-05 2008-01-17 The Trustees Of The University Of Pennsylvania Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
CN103589692B (zh) * 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
EP2158211B1 (en) 2007-05-31 2016-08-10 Medigene AG Mutated structural protein of a parvovirus
WO2011072204A1 (en) 2009-12-10 2011-06-16 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
ES2926774T3 (es) * 2013-03-15 2022-10-28 Univ North Carolina Chapel Hill Métodos y composiciones para vectores AAV de doble unión de glicano
WO2015137802A1 (en) * 2014-03-10 2015-09-17 Uniqure Ip B.V. Further improved aav vectors produced in insect cells
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
US10577627B2 (en) * 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
US10550405B2 (en) * 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
EP4706687A3 (en) 2017-06-27 2026-07-15 Regeneron Pharmaceuticals, Inc. Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells
SI3645551T1 (sl) 2017-06-27 2024-06-28 Regeneron Pharmaceuticals, Inc. S tropizmi spremenjeni rekombinantni virusni vektorji in njihova uporaba za tarčni vnos genetskega materiala v človeške celice
US12421525B2 (en) * 2018-02-28 2025-09-23 University of Pittsburgh—of the Commonwealth System of Higher Education Conjugates comprising AAVs and CAS9 polypeptides
AU2020283537A1 (en) * 2019-05-24 2021-12-16 Regeneron Pharmaceuticals, Inc. Modified viral particles and uses thereof

Similar Documents

Publication Publication Date Title
Wagner et al. Synthetic biology: emerging concepts to design and advance adeno‐associated viral vectors for gene therapy
US20240197918A1 (en) Tissue-targeted modified aav capsids and methods of use thereof
AU2020214831A1 (en) Systems for evolved adeno-associated viruses (AAVs) for targeted delivery
JP2023171525A (ja) Aavキメラ
KR20190032375A (ko) 신규 아데노-관련 바이러스 캡시드 단백질
CN112041442A (zh) 用于逃避抗体的病毒载体的方法和组合物
US12398403B2 (en) Methods for the manufacture of recombinant viral vectors
IL317938A (en) Recombinant viral vectors with altered tropism and their uses for the targeted introduction of genetic material into human cells
JP2025119015A (ja) 改変ウイルス粒子およびその使用
JP2024050766A (ja) 改変ウイルスカプシド
JP2024540181A5 (cg-RX-API-DMAC7.html)
JP2021520837A5 (cg-RX-API-DMAC7.html)
US20180016328A1 (en) Anti-tau constructs
JP7688572B2 (ja) ガラクトース血症の処置のための遺伝子治療
TW201920676A (zh) 具有經修飾之磷脂酶區域的腺相關病毒(aav)
JP2025517628A (ja) 新規の組換えaav vp2融合ポリペプチド
AR123948A1 (es) ANTICUERPOS ANTI-TNF-a VECTORIZADOS PARA INDICACIONES OCULARES
US20240050476A1 (en) Combination of deoxyribonuclease enzyme and cell therapies for treatment of cancer
RU2021133286A (ru) Модифицированные вирусные частицы и пути их применения
Mann et al. Enhanced transduction of P2X7-expressing cells with recombinant rAAV vectors
Weinmann Massively parallel in vivo characterization of novel adeno-associated viral (AAV) capsids using DNA/RNA barcoding and next generation sequencing
RU2020101596A (ru) Рекомбинантные вирусные частицы с модифицированным тропизмом и пути их применения для нацеленного введения генетического материала в клетки человека
RU2024111148A (ru) Вирусные частицы, перенацеленные на скелетные мышцы
Xu et al. Capsid modification of adeno-associated virus and tumor targeting gene therapy
HK40113792A (en) Capsid variants and methods of using the same